ImmunoGenesis

Private

Houston, TexasHealthcare & Life Scienceshttps://www.immunogenesis.com/

Last Round

Grant

Dec 4, 2025

Total Funding Raised

$70.7M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

ImmunoGenesis is a biopharmaceutical company that develops immuno-oncology therapeutics designed to enhance immune responses in cold tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

immunotherapyimmune-excluded tumorsclinical-stage biotechoncology drug developmentcancer immunotherapybiotech startupimmunotherapy resistancemulti-omicsbiomarker discoveryclinical trialsprecision oncologydrug pipelineai-driven drug discoverypatient stratificationdrug candidate

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImmunoGenesis Comps

Public and private peers based on sector, stage, and business model.

ImmunoGenesis comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ImmunoGenesis Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Dec 4, 2025
Series A	Apr 1, 2024
VC Round	Jun 27, 2023
Grant	Aug 19, 2020

View all Funding Rounds

ImmunoGenesis Investors

Notable investors and investment history

ImmunoGenesis investors
Investor	Rounds
The University of Texas MD Anderson Cancer Center	VC Round
Cancer Focus Fund	Series A, VC Round
Cancer Prevention and Research Institute of Texas (CPRIT)	Grant

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

May 17, 2026
Monthly visitors increased 55% MoM.
Apr 15, 2026
Poster presentation at the AACR 2026 Annual Meeting.

View all signals

ImmunoGenesis Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

ImmunoGenesis Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ImmunoGenesis's valuation, stock price, and market status.

Firmographic Details

HeadquartersHouston, Texas

Employee Range15

Year Founded2019

Last FundingDec 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.